CLCS Stock Overview
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Cell Source, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.74 |
| 52 Week Low | US$0.0002 |
| Beta | -150.9 |
| 1 Month Change | -99.97% |
| 3 Month Change | -99.96% |
| 1 Year Change | -33.33% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLCS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -99.9% | -2.5% | -3.2% |
| 1Y | -33.3% | -3.7% | 19.3% |
Return vs Industry: CLCS underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: CLCS underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| CLCS volatility | |
|---|---|
| CLCS Average Weekly Movement | 58.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CLCS's share price has been volatile over the past 3 months.
Volatility Over Time: CLCS's weekly volatility has decreased from 19911% to 58% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1 | Itamar Shimrat | cell-source.com |
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases.
Cell Source, Inc. Fundamentals Summary
| CLCS fundamental statistics | |
|---|---|
| Market cap | US$8.20k |
| Earnings (TTM) | -US$6.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CLCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLCS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.80m |
| Earnings | -US$6.80m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -59.9% |
How did CLCS perform over the long term?
See historical performance and comparison